Thu, 03 Dec 2015 13:30:00 GMT ~ Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Adults With X-Linked Hypophosphatemia (XLH)
[GlobeNewswire] - NOVATO, Calif., Dec. 03, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation ...
Wed, 02 Dec 2015 21:30:00 GMT ~ Ultragenyx to Present at the Oppenheimer Annual Healthcare Conference
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, ...
Wed, 02 Dec 2015 13:30:00 GMT ~ Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...
Link: http://www.otcmarkets.com/stock/RARE/company-info Ticker: $RARE OTC Market Place: Not Available CIK code: not found Company name: Ultragenyx Pharmaceutical Inc. Incorporated In: $RARE share structure
## source: otcmarkets.com
Market Value: Not Available Shares Outstanding: Not Available Float: Not Available Authorized Shares: Not Available Par Value: Not Available